The Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC) (ORR) of 97% from Post-Hoc Analysis of a Phase 2 to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC)
Main Article Content
Keywords
BCC
Abstract
Introduction
Objective response rate (ORR), defined as the percentage of patients achieving a complete or partial response to treatment, is a critical endpoint in clinical trials assessing the efficacy of new therapies in solid tumors, including BCC.
We performed a post-hoc analysis exploring ORR as a potential primary endpoint for future studies evaluating the efficacy of VP-315, an intratumorally injected, chemotherapeutic oncolytic peptide.
Objective
To evaluate the effect of various VP-315 8 mg dosing regimens on antitumor response in subjects with BCC.
Methods
Eighty-two subjects with up to 2 target BCC tumors (total 91 tumors) were treated intratumorally with VP-315 for up to 2 weeks. Cohort 3 was not enrolled based on results from Cohorts 1-2. Each 7-day treatment week was comprised of 2 or 3 consecutive treatment days followed by a no-treatment period of at least 4 days. Dosing scheme:
Cohort 1: (n=6) Tumor injected 3 days consecutively (3X/week 4 mg loading dose Day 1 followed by 8 mg dose).
Cohort 2: (n=3) Tumor injected 3 days consecutively (3X/week 8 mg dose).
Cohort 4: (n=36) Each tumor was injected 2 days consecutively (2X/week 8 mg split dose*).
Cohort 5: (n=37) Each tumor was injected 3 days consecutively (3X/week 8 mg split dose*).
* Dose split into 2 injections, 30% injected initially; 70% injected 15-30 minutes later.
Post-hoc evaluation by ORR was based on response defined a priori as absence of disease progression and ≥30% reduction in lesion size from baseline, or complete resolution of ulceration in all target lesions. Complete response was based upon objective response with no residual BCC on post-treatment excisional biopsy. Partial response was objective response with presence of residual BCC.
Results
Eighty-two subjects (n=91 tumors) treated with VP-315 had a calculated ORR of 97%. Response rates were: 52% complete response and 45% partial response. No TRSAEs were reported. TRAEs were mostly mild to moderate.
Conclusion
These results support further investigation of ORR as a reliable endpoint for VP-315 in future BCC studies. Additional research using VP-315 as a potential non-surgical immunotherapy for BCC as a first line therapy in a primary or neoadjuvant setting is warranted.
References
2. Eike LM, et al. Oncotarget. 2015;6(33):34910-23.
3. Ozatli, et al. World J Clin Oncol. 2020 Feb 24;11(2):53–73
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.